238 related articles for article (PubMed ID: 24097861)
1. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
[TBL] [Abstract][Full Text] [Related]
4. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?
Lee RJ; Smith MR
Clin Cancer Res; 2014 Feb; 20(3):525-7. PubMed ID: 24284057
[TBL] [Abstract][Full Text] [Related]
8. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
Stern PH; Alvares K
J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
Graham TJ; Box G; Tunariu N; Crespo M; Spinks TJ; Miranda S; Attard G; de Bono J; Eccles SA; Davies FE; Robinson SP
J Natl Cancer Inst; 2014 Apr; 106(4):dju033. PubMed ID: 24634505
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
Ishii A; Shigemura K; Kitagawa K; Sung SY; Chen KC; Yi-Te C; Liu MC; Fujisawa M
Anticancer Res; 2020 Sep; 40(9):5107-5114. PubMed ID: 32878799
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture
Pan T; Martinez M; Hubka KM; Song JH; Lin SC; Yu G; Lee YC; Gallick GE; Tu SM; Harrington DA; Farach-Carson MC; Lin SH; Satcher RL
Mol Cancer Ther; 2020 Jun; 19(6):1266-1278. PubMed ID: 32220969
[TBL] [Abstract][Full Text] [Related]
14. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
Lee YC; Lin SC; Yu G; Cheng CJ; Liu B; Liu HC; Hawke DH; Parikh NU; Varkaris A; Corn P; Logothetis C; Satcher RL; Yu-Lee LY; Gallick GE; Lin SH
Cancer Res; 2015 Nov; 75(22):4949-59. PubMed ID: 26530902
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms.
Scott AJ; Arcaroli JJ; Bagby SM; Yahn R; Huber KM; Serkova NJ; Nguyen A; Kim J; Thorburn A; Vogel J; Quackenbush KS; Capasso A; Schreiber A; Blatchford P; Klauck PJ; Pitts TM; Eckhardt SG; Messersmith WA
Mol Cancer Ther; 2018 Oct; 17(10):2112-2122. PubMed ID: 30026382
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
Lee RJ; Saylor PJ; Michaelson MD; Rothenberg SM; Smas ME; Miyamoto DT; Gurski CA; Xie W; Maheswaran S; Haber DA; Goldin JG; Smith MR
Clin Cancer Res; 2013 Jun; 19(11):3088-94. PubMed ID: 23553848
[TBL] [Abstract][Full Text] [Related]
18. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
20. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]